Hyperlipidemia Promotes Anti-Donor Th17 Responses That Accelerate Allograft Rejection

American Journal of Transplantation

Volumn 15, Issue 9, 2015, Pages 2336-2345

  Yuan, J ^a   Bagley, J ^a   Iacomini, J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

hyperlipidemia; rejection; rejection: T cell mediated (TCMR); T cell biology

Indexed keywords

ALLOANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; MONOCLONAL ANTIBODY;

ALLOGRAFT; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT SURVIVAL; HEART GRAFT; HYPERLIPIDEMIA; LIPID DIET; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CELL DIFFERENTIATION; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; REGULATORY T LYMPHOCYTE;

ALLOGRAFTS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL DIFFERENTIATION; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HEART TRANSPLANTATION; HYPERLIPIDEMIAS; IMMUNE TOLERANCE; INTERLEUKIN-17; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84939568756     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13350     Document Type: Article

References (48)

1. Strom TB, Roy-Chaudhury P, Manfro R, et al., The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol 1996; 8: 688-693.
2. Le Moine A, Goldman M, Abramowicz D,. Multiple pathways to allograft rejection. Transplantation 2002; 73: 1373-1381.
3. Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P,. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997; 100: 550-557.
4. Wood KJ, Goto R,. Mechanisms of rejection: current perspectives. Transplantation 2012; 93: 1-10.
5. Rocha PN, Plumb TJ, Crowley SD, Coffman TM,. Effector mechanisms in transplant rejection. Immunol Rev 2003; 196: 51-64.
6. Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G,. Atherosclerosis as an inflammatory disease. Curr Pharm Des 2012; 18: 4266-4288.
7. Libby P, Ridker PM, Hansson GK,. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-325.
8. Hansson GK,. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
9. Ross R,. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126.
10. Tedgui A, Mallat Z,. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
11. Weber C, Zernecke A, Libby P,. The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat Rev Immunol 2008; 8: 802-815.
12. Smith E, Prasad K-MR, Butcher M, et al., Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010; 121: 1746-1755.
13. Ng HP, Burris RL, Nagarajan S,. Attenuated atherosclerotic lesions in apoE-Fcgamma-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells. J Immunol 2011; 187: 6082-6093.
14. Gao Q, Jiang Y, Ma T, et al., A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 2010; 185: 5820-5827.
15. Stehlik J, Edwards LB, Kucheryavaya AY, et al., The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report-2011. J Heart Lung Transplant 2011; 30: 1078-1094.
16. Pflugfelder PW, Huff M, Oskalns R, Rudas L, Kostuk WJ,. Cholesterol-lowering therapy after heart transplantation: A 12-month randomized trial. J Heart Lung Transplant 1995; 14: 613-622.
17. Zakliczynski M, Boguslawska J, Wojniak E, et al., In the era of the universal use of statins dyslipidemia's are still common in heart transplant recipients: A cross-sectional study. Transplant Proc 2011; 43: 3071-3073.
18. Shi C, Lee W-S, Russell ME, et al., Hypercholesterolemia exacerbates transplant arteriosclerosis via increased neointimal smooth muscle cell accumulation. Circulation 1997; 96: 2722-2728.
19. Russell PS, Chase CM, Colvin RB,. Accelerated atheromatous lesions in mouse hearts transplanted to apolipoprotein-E-deficient recipients. Am J Pathol 1996; 149: 91-99.
20. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N,. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992; 89: 4471-4475.
21. Whitman SC,. A practical approach to using mice in atherosclerosis research. Clin Biochem Rev 2004; 25: 81-93.
22. Plump AS, Breslow JL,. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr 1995; 15: 495-518.
23. Moghadasian MH, McManus BM, Nguyen LB, et al., Pathophysiology of apolipoprotein E deficiency in mice: Relevance to apo E-related disorders in humans. FASEB J 2001; 15: 2623-2630.
24. Davis HR, Jr., Hoos LM, Tetzloff G, et al., Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice. Arterioscler Thromb Vasc Biol 2007; 27: 841-849.
25. Corry RJ, Winn HJ, Russell PS,. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343.
26. Lim H, Kim YU, Sun H, et al., Proatherogenic conditions promote autoimmune T helper 17 cell responses in vivo. Immunity 2014; 40: 153-165.
27. Bagley J, Sawada T, Wu Y, Iacomini J,. A critical role for interleukin 4 in activating alloreactive CD4 T cells. Nat Immunol 2000; 1: 257-261.
28. Sayegh MH, Wu Z, Hancock WW, et al., Allograft rejection in a new allospecific CD4+ TCR transgenic mouse. Am J Transplant 2003; 3: 381-389.
29. Yuan X, Ansari MJ, D'Addio F, et al., Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci USA 2009; 106: 10734-10739.
30. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al., A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205: 3133-3144.
31. Vanaudenaerde BM, Dupont LJ, Wuyts WA, et al., The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J 2006; 27: 779-787.
32. Van Kooten C, Boonstra JG, Paape ME, et al., Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 1998; 9: 1526-1534.
33. Tang JL, Subbotin VM, Antonysamy MA, Troutt AB, Rao AS, Thomson AW,. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation 2001; 72: 348-350.
34. Itoh S, Nakae S, Axtell RC, et al., IL-17 contributes to the development of chronic rejection in a murine heart transplant model. J Clin Immunol 2010; 30: 235-240.
35. Yoshida S, Haque A, Mizobuchi T, et al., Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant 2006; 6: 724-735.
36. Antonysamy MA, Fanslow WC, Fu F, et al., Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999; 162: 577-584.
37. Loong CC, Hsieh HG, Lui WY, Chen A, Lin CY,. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002; 197: 322-332.
38. Vokaer B, Van Rompaey N, Lemaitre PH, et al., Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection. J Immunol 2010; 185: 3417-3425.
39. Litjens NH, van de Wetering J, van Besouw NM, Betjes MG,. The human alloreactive CD4+ T-cell repertoire is biased to a Th17 response and the frequency is inversely related to the number of HLA class II mismatches. Blood 2009; 114: 3947-3955.
40. Li J, Simeoni E, Fleury S, et al., Gene transfer of soluble interleukin-17 receptor prolongs cardiac allograft survival in a rat model. Eur J Cardiothorac Surg 2006; 29: 779-783.
41. Agorogiannis EI, Regateiro FS, Howie D, Waldmann H, Cobbold SP,. Th17 cells induce a distinct graft rejection response that does not require IL-17A. Am J Transplant 2012; 12: 835-845.
42. Tiriveedhi V, Takenaka M, Ramachandran S, et al., T regulatory cells play a significant role in modulating MHC class I antibody-induced obliterative airway disease. Am J Transplant 2012; 12: 2663-2674.
43. Burlingham WJ, Love RB, Jankowska-Gan E, et al., IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117: 3498-3506.
44. Sullivan JA, Adams AB, Burlingham WJ,. The emerging role of TH17 cells in organ transplantation. Transplantation 2014; 97: 483-489.
45. Zhang HL, Wu J, Zhu J,. The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Dev Immunol 2010; 2010: 186813.
46. Cimato TR, Palka BA, Lang JK, Young RF,. LDL cholesterol modulates human CD34+ HSPCs through effects on proliferation and the IL-17 G-CSF axis. PLoS ONE 2013; 8: e73861.
47. Plump AS, Smith JD, Hayek T, et al., Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
48. Schonder KS, McKaveney TP, Lynch KJ,. Retrospective analysis of hyperlipidemia management in a transplant population. Pharmacotherapy 2005; 25: 918-923.